Related Experiment Video

Updated: May 9, 2026

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo

Sarah A Loddick1, Sarah J Ross, Andrew G Thomason

  • 1Corresponding Author: A. Nigel Brooks, Oncology iMED, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom. Nigel.Brooks@astrazeneca.com.

Molecular Cancer Therapeutics
|July 18, 2013
PubMed

Insights

AZD3514, a novel drug, effectively inhibits androgen receptor (AR) signaling in prostate cancer models. It targets both androgen-dependent and -independent pathways, showing promise for castration-resistant prostate cancer (CRPC) treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC) progression after initial therapies.
  • Targeting AR remains crucial for treating advanced prostate cancer.

Purpose of the Study:

  • To biologically characterize AZD3514, an orally bioavailable drug targeting AR signaling.
  • To evaluate AZD3514's efficacy in preclinical models of prostate cancer.

Main Methods:

  • In vitro and in vivo studies to assess AZD3514's mechanisms of action.
  • Evaluation of AZD3514's effect on testosterone-driven seminal vesicle development in rats.
  • Assessment of AZD3514's antitumor activity in androgen-dependent and CRPC mouse models.

Main Results:

  • AZD3514 inhibits both androgen-dependent and -independent AR signaling.
  • The drug demonstrated dual mechanisms: inhibiting AR nuclear translocation and downregulating AR levels.
  • AZD3514 showed efficacy in inhibiting tumor growth in preclinical models, including a CRPC model.

Conclusions:

  • AZD3514 is a potent inhibitor of AR signaling with potential for CRPC treatment.
  • Its dual mechanism of action and oral bioavailability make it a promising therapeutic candidate.
  • AZD3514 is currently undergoing Phase I clinical trials.

More Related Videos

Large Scale Zebrafish-Based In vivo Small Molecule Screen07:03

Large Scale Zebrafish-Based In vivo Small Molecule Screen

Published on: December 30, 2010

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...